SLGL Sol-Gel Technologies Ltd

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Cantor Global Healthcare Conference, taking place virtually from September 27th – 30th, 2021.

Cantor Global Healthcare Conference Presentation Information:
FormatFireside chat discussion and 1-on-1 meetings
Speaker:Dr. Alon Seri-Levy, Chief Executive Officer and Mr. Gilad Mamlok, Chief Financial Officer
Date:Thursday, September 30th
Time:Discussion available on demand beginning Thursday, September 30th 10:40 a.m. ET (TRACK 3)
To ListenTo listen to the discussion, click . A replay will be archived for 30 days at this link (or go to to access within the Investors/Events and Presentations section).

About Sol-Gel Technologies

Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. Both product candidates are exclusively licensed for U.S. commercialization with Galderma.

The Company’s pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment of palmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment of plaque psoriasis and other dermatologic indications.

For additional information, please visit .

Contact:

Irina Koffler

Investor relations, LifeSci Advisors



Sol-Gel Technologies

Gilad Mamlok

Chief Financial Officer



EN
22/09/2021

Underlying

SLGLSol-Gel Technologies Ltd

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sol-Gel Technologies Ltd

 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-...

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today provided an update following the unblinding of clinical data from its vehicle-controlled proof-of-concept Phase 1b study of SGT-210 on Darier disease. Following unblinding, the data from the vehicle-controlled Phase 1b proof-of-concept study did not show differentiation between SGT-210 and vehicle on t...

December 17, 2025 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corp...

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments ...

November 20, 2025 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Announces Health Canada Approval of EPSOLAY®

Sol-Gel Announces Health Canada Approval of EPSOLAY® NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, a Phase-1b, double blinded clinical trial of SGT-210 (erlotinib ointment, 5%) on Darier disease patients and with two approved large-category dermatology products, TWYNEO and EPSOLAY, announced today that on August 27, 2025 Health Canada issued a Notice of Compliance (...

September 4, 2025 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Cor...

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease is ongoingSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S. for a total consideration of $16 million to be received during 2025Following recent transactions, Sol-Gel’s cash runway is expected to extend into the first quarter of 2027 NESS ZIO...

August 15, 2025 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Reports First Quarter 2025 Results

Sol-Gel Reports First Quarter 2025 Results NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025 Total revenue in the first quarter was $1 million compared to $0.5 million revenues for the same period in 2024. Research and development expenses were $8.8 million compared to $5.3 million in the same p...

May 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch